Heilongjiang ZBD Pharmaceutical Co Ltd (603567) — Net Asset Quality Index
Heilongjiang ZBD Pharmaceutical Co Ltd (603567) has a Net Asset Quality Index of 61.8% as of September 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥11.80 Billion minus total liabilities of CN¥4.51 Billion yields net assets of CN¥7.29 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 603567 days of operational coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Heilongjiang ZBD Pharmaceutical Co Ltd Net Asset Quality Index Over Time (2011–2024)
This chart shows how Heilongjiang ZBD Pharmaceutical Co Ltd's Net Asset Quality Index has evolved across 14 annual periods from 2011 to 2024. As of September 2025, the index stands at 61.8%, representing net assets of CN¥7.29 Billion against total assets of CN¥11.80 Billion CNY. Explore 603567 cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Heilongjiang ZBD Pharmaceutical Co Ltd (2011–2024)
The table below presents the year-by-year Net Asset Quality Index for Heilongjiang ZBD Pharmaceutical Co Ltd from 2011 to 2024, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Heilongjiang ZBD Pharmaceutical Co Ltd (603567) market capitalisation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 65.2% | CN¥8.29 Billion | CN¥12.71 Billion | CN¥4.42 Billion | ▲ +0.7 pp |
| 2023 | 64.5% | CN¥8.04 Billion | CN¥12.47 Billion | CN¥4.43 Billion | ▲ +3.6 pp |
| 2022 | 60.9% | CN¥7.11 Billion | CN¥11.68 Billion | CN¥4.57 Billion | ▼ -0.4 pp |
| 2021 | 61.3% | CN¥7.05 Billion | CN¥11.51 Billion | CN¥4.45 Billion | ▲ +7.5 pp |
| 2020 | 53.8% | CN¥5.50 Billion | CN¥10.23 Billion | CN¥4.73 Billion | ▼ -4.4 pp |
| 2019 | 58.2% | CN¥5.25 Billion | CN¥9.02 Billion | CN¥3.77 Billion | ▼ -2.7 pp |
| 2018 | 60.9% | CN¥4.98 Billion | CN¥8.18 Billion | CN¥3.20 Billion | ▼ -7.0 pp |
| 2017 | 68.0% | CN¥4.68 Billion | CN¥6.89 Billion | CN¥2.21 Billion | ▲ +0.9 pp |
| 2016 | 67.1% | CN¥4.31 Billion | CN¥6.42 Billion | CN¥2.11 Billion | ▲ +0.2 pp |
| 2015 | 66.9% | CN¥3.98 Billion | CN¥5.95 Billion | CN¥1.97 Billion | ▲ +6.6 pp |
| 2014 | 60.3% | CN¥2.17 Billion | CN¥3.60 Billion | CN¥1.43 Billion | ▲ +6.5 pp |
| 2013 | 53.7% | CN¥1.75 Billion | CN¥3.25 Billion | CN¥1.50 Billion | ▼ -8.3 pp |
| 2012 | 62.0% | CN¥1.32 Billion | CN¥2.13 Billion | CN¥808.30 Million | ▼ -2.1 pp |
| 2011 | 64.1% | CN¥923.09 Million | CN¥1.44 Billion | CN¥516.70 Million | — |